A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Public ClinicalTrials.gov record NCT04254107. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).
Study identification
- NCT ID
- NCT04254107
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 133 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 29, 2020 (Actual)
- Primary completion
- Dec 1, 2023 (Actual)
- Completion
- Dec 1, 2023 (Actual)
- Last update posted
- Feb 10, 2025
2020 – 2023
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85710 | — |
| City of Hope | Duarte | California | 91010-3000 | — |
| California Research Institute | Los Angeles | California | 90027 | — |
| University of California, San Francisco | HDFCCC - Hematopoietic Malignancies | San Francisco | California | 94134 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Johns Hopkins Medical Center | Baltimore | Maryland | 21287 | — |
| Maryland Oncology Hematology, P.A. | Rockville | Maryland | 20850 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Minnesota Oncology Hematology P.A. | Minneapolis | Minnesota | 55404 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Weill Cornell Medicine | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Wake Forest Baptist Medical Center / Wake Forest University | Winston-Salem | North Carolina | 27157 | — |
| University of Cincinnati Cancer Institute | Cincinnati | Ohio | 45219 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37204 | — |
| Texas Oncology - Austin Midtown | Austin | Texas | 78705 | — |
| Texas Oncology - Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center / University of Texas | Houston | Texas | 77030 | — |
| Texas Oncology - Northeast Texas | Tyler | Texas | 75702 | — |
| Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care | Blacksburg | Virginia | 24060 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Carbone Cancer Center / University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04254107, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04254107 live on ClinicalTrials.gov.